Could This Company Challenge Eli Lilly and Novo Nordisk in the Weight Loss Market?
Novo Nordisk (NYSE:NVO) has been a pioneer in the market for weight loss drugs, but Eli Lilly (NYSE:LLY) has since emerged as the leader. Both drugmakers have deep pipelines that could allow them to remain ahead of their competitors in the coming years as the anti-obesity area continues to expand rapidly. But could another pharmaceutical giant eventually take the lead? One of the more likely candidates to do so might be Roche (OTC:RHHBY) , and recent developments have shown just how promising its leading candidate is. Let's find out what this could mean for investors looking to capitalize on the weight loss market. Image source: The Motley Fool. Continue reading